Alzheimer’s Placebo May Become Disease-Modifying Drug For Affiris
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.